Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
A legfontosabb adatok
- Hol
- Madison (Egyesült Államok)A helyszín megnézése
- Fázis
- 3. fázis
Helyszínek itt: Egyesült Államok
- UW Hospital and ClinicsMadison, Egyesült ÁllamokContact: Brad Astor, PhD (sub-investigator)Résztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- University of Wisconsin, Madison
- Azonosító
- NCT06407232
- A regiszteradat frissítve
- 2026. június 11.
- Eredeti leírás
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.A teljes eredeti leírásKevesebb
An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Bevonási feltételek: undergone kidney or simultaneous kidney/pancreas transplant; high-risk CMV serostatus (D+/R-) at time of transplant; develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative); demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening; able to provide informed consent to participate.
Kizáró feltételek: currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent; develop ganciclovir-resistant CMV infection; contraindication to letermovir or its excipients; unable or unwilling, in the opinion of the Investigator, to comply with the protocol; pregnant or breastfeeding.